15 March 2021
Visiongain has published a new report on Women’s Health Diagnostics Market Report to 2031: Forecasts by Application (Breast Cancer Testing (Mammography Systems, Breast Cancer Tumor Marker Tests. Blood Chemistries and Blood Cell Count, Biopsies, and Other Diagnostic Imaging Tests), Infectious Disease Testing (Urinary Tract Infection Testing, MRSA Testing, Hepatitis Testing, Tuberculosis Testing, and Other Infectious Disease Testing), Cervical Cancer Testing (Pap Smear and HPV Testing), Osteoporosis Testing (Bone Densitometry and In Vitro Blood Tests), Sexually Transmitted Disease Testing (Chlamydia Trachomatis And Neisseria Gonorrhoeae (Ct/Ng) Testing, HIV Testing, and Other Sexually Transmitted Diseases), Prenatal Genetic Screening and Carrier Testing (Cystic Fibrosis, Down Syndrome and Edward Syndrome, TORCH Infections, and Other Diseases), Ultrasound (OB/GYN Imaging and Breast Imaging), Pregnancy and Fertility Testing (Lab-based Testing and Fertility Monitors), Ovarian Cancer Testing(Ovarian Cancer Tumor Marker Tests, Diagnostic Imaging Tests, and Other Tests)), By End User (Hospitals and Home Care) PLUS COVID-19 Recovery Scenarios.
Global Women’s Health Diagnostics market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.
COVID-19 Impact on Women’s Health Diagnostics Market
COVID-19 pandemic has affected more than 200 countries worldwide. Companies have been pressured to upsurge production capacity and raise the supply of products and other commodities. The pandemic has negatively impacted all the economies and industries across the world. Visiongain has anticipated four scenarios for the Women’s Health Diagnostics market in the given timeframe, viz., V, U, W, and L. The most favorable scenario for this market is expected to be the V scenario which is reliant on the entire pharmaceutical supply chain. This scenario is likely when countries ease lockdown implementations and have actual treatment and vaccines in place.
Rising Incidence of Chronic and Lifestyle-Related Disorders in Women
The growth in socio-economic impact on women across the globe is increasing. Hence, the necessity for their well-being is vital. The rising number of women professionals and the necessity for care towards their well-being for their work efficacy can support the upsurge of the women's healthcare market in the given timeframe. Health situation, unique to women, such as infertility, menopause, polycystic ovarian syndrome, and cancers such as cervical cancer, breast cancer, and urological disorders needs special care. Chronic disorders, like heart disease and stroke, cause more mortality rates.
As per the Centers for Disease Control and Prevention (CDC), nearly 1.70 million people die from a chronic disease every year in the USA. Although chronic diseases are the major reason for death for men and women alike because women face unique health issues. Around 37% of women suffer from chronic diseases, compared to 30% of men. Initial identification of any health issues with the help of diagnostic devices, for instance, breast MRI, ultrasound, and pregnancy and fertility testing are basic. Hence, the increase in demand for women's health solutions for different medical situations pushes the target industry growth further. The growing awareness regarding women's health solutions to rural areas across the globe is expected to gain significant growth during the forecast period.
Growing Adoption of Point-Of-Care and Rapid Diagnostic Tests
The target market growth is predominantly attributed to the growing acceptance of point-of-care and quick diagnostic tests, the rising number of private diagnostic centers, and the growing awareness regarding fertility testing in women and initiatives taken by health organizations and government. Besides, improving healthcare infrastructure in developing countries and the increasing number of regulatory endorsements for immunoassay techniques further offer lucrative growth opportunities for the global key players operating in the women's health diagnostics market. However, the shortage of skilled laboratory technicians and the high price of diagnostic imaging systems & procedures may hinder the target industry growth at a certain point.
Some of the major companies operating in the global Women’s Health Diagnostics market are Siemens AG, Becton, Dickinson, and Company (BD), Alere Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Koninklijke Philips N.V., GE Healthcare, Quest Diagnostics Inc., PerkinElmer Inc., and bioMÃ©rieux SA.
To tap into the emerging market, key players are focusing on product launches, expansion, and mergers & acquisitions. For instance, In May 2019, Cardinal Health introduced the RADIAL 360 range in the U.S. on the other hand, In May 2019, Roche introduced the VENTANA HER2 Dual ISH DNA Probe Cocktail test for identifying the HER2 biomarker in breast cancer and gastric. This will help to attain a major market share for the company.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.
29 September 2022
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.